Free Trial

Estrella Immunopharma (ESLA) Competitors

$1.00 -0.01 (-0.99%)
Closing price 05/22/2025 03:58 PM Eastern
Extended Trading
$1.01 +0.01 (+1.00%)
As of 05/22/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESLA vs. KRRO, SLS, FTLF, NKTX, CYBN, TNGX, NLTX, EPRX, ACRS, and ADCT

Should you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Korro Bio (KRRO), SELLAS Life Sciences Group (SLS), FitLife Brands (FTLF), Nkarta (NKTX), Cybin (CYBN), Tango Therapeutics (TNGX), Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Aclaris Therapeutics (ACRS), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry.

Estrella Immunopharma vs.

Korro Bio (NASDAQ:KRRO) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, community ranking, dividends, analyst recommendations, profitability, earnings and valuation.

In the previous week, Korro Bio had 7 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for Korro Bio and 0 mentions for Estrella Immunopharma. Korro Bio's average media sentiment score of 0.59 beat Estrella Immunopharma's score of 0.00 indicating that Korro Bio is being referred to more favorably in the media.

Company Overall Sentiment
Korro Bio Positive
Estrella Immunopharma Neutral

Korro Bio has a beta of 2.66, suggesting that its stock price is 166% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are held by institutional investors. 4.6% of Korro Bio shares are held by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Estrella Immunopharma has lower revenue, but higher earnings than Korro Bio. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Korro Bio$4.82M28.85-$81.17M-$9.44-1.57
Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.85

Korro Bio presently has a consensus price target of $102.43, suggesting a potential upside of 591.62%. Estrella Immunopharma has a consensus price target of $16.00, suggesting a potential upside of 1,500.00%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Korro Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Korro Bio
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
Estrella Immunopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Korro Bio received 31 more outperform votes than Estrella Immunopharma when rated by MarketBeat users.

CompanyUnderperformOutperform
Korro BioOutperform Votes
32
100.00%
Underperform Votes
No Votes
Estrella ImmunopharmaOutperform Votes
1
100.00%
Underperform Votes
No Votes

Korro Bio's return on equity of -50.25% beat Estrella Immunopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Korro BioN/A -50.25% -38.48%
Estrella Immunopharma N/A -195.77%-157.28%

Summary

Korro Bio beats Estrella Immunopharma on 12 of the 16 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESLA vs. The Competition

MetricEstrella ImmunopharmaBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$36.17M$2.93B$5.33B$8.39B
Dividend YieldN/A1.64%5.21%4.11%
P/E Ratio-3.8531.1826.7119.71
Price / SalesN/A398.78386.08120.53
Price / CashN/A168.6838.2534.62
Price / Book8.333.236.774.50
Net Income-$7.31M-$72.35M$3.23B$248.22M
7 Day Performance4.28%2.49%0.48%-0.78%
1 Month Performance-1.95%2.45%9.10%11.53%
1 Year PerformanceN/A-24.98%18.56%8.99%

Estrella Immunopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESLA
Estrella Immunopharma
1.4842 of 5 stars
$1.00
-1.0%
$16.00
+1,500.0%
-1.5%$36.17MN/A-3.85N/A
KRRO
Korro Bio
2.0182 of 5 stars
$15.98
+2.7%
$112.75
+605.6%
-70.5%$146.12M$4.82M-1.6970Analyst Revision
Gap Down
SLS
SELLAS Life Sciences Group
0.3236 of 5 stars
$1.54
-1.3%
N/A+23.1%$145.60M$1M-2.2310
FTLF
FitLife Brands
4.4166 of 5 stars
$15.41
-1.9%
$20.50
+33.0%
+0.0%$144.61M$64.47M18.2420Analyst Downgrade
NKTX
Nkarta
1.9468 of 5 stars
$2.02
+4.7%
$14.83
+634.3%
-74.6%$143.34MN/A-1.07140Positive News
Gap Up
CYBN
Cybin
2.7033 of 5 stars
$6.62
-6.1%
$86.00
+1,199.1%
N/A$142.18MN/A-1.5150
TNGX
Tango Therapeutics
1.878 of 5 stars
$1.31
+14.9%
$12.33
+841.5%
-74.8%$141.62M$42.07M-1.1190Positive News
NLTX
Neoleukin Therapeutics
N/A$14.73
-1.8%
N/A-42.7%$138.43MN/A-4.7490Gap Up
High Trading Volume
EPRX
Eupraxia Pharmaceuticals
2.1117 of 5 stars
$3.86
+1.4%
$10.50
+172.4%
+28.3%$138.20MN/A-5.3529
ACRS
Aclaris Therapeutics
2.8652 of 5 stars
$1.25
-0.8%
$10.67
+753.3%
+9.6%$135.35M$18.72M-2.40100Positive News
ADCT
ADC Therapeutics
2.6865 of 5 stars
$1.35
+5.9%
$7.75
+476.2%
-39.8%$133.39M$70.84M-0.56310

Related Companies and Tools


This page (NASDAQ:ESLA) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners